Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $736,000 - $809,248
1,600 Added 2.49%
65,900 $30.6 Million
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $628,496 - $776,848
1,600 Added 2.55%
64,300 $30.1 Million
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $1.43 Million - $1.56 Million
-3,500 Reduced 5.29%
62,700 $26.2 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $89,180 - $106,776
-260 Reduced 0.39%
66,200 $26.9 Million
Q3 2023

Nov 09, 2023

BUY
$338.18 - $362.46 $8.61 Million - $9.23 Million
25,460 Added 62.1%
66,460 $23.1 Million
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $4.24 Million - $4.75 Million
13,500 Added 49.09%
41,000 $14.4 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $7.02 Million - $8.01 Million
24,800 Added 918.52%
27,500 $8.66 Million
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $771,552 - $867,996
2,700 New
2,700 $779,000
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $497,752 - $586,660
2,248 Added 7.54%
32,048 $8.36 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $485,184 - $612,476
-2,741 Reduced 8.42%
29,800 $6.54 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $2.79 Million - $3.29 Million
14,900 Added 84.46%
32,541 $6.56 Million
Q1 2021

May 12, 2021

SELL
$207.02 - $241.31 $6.4 Million - $7.46 Million
-30,924 Reduced 63.68%
17,641 $3.79 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $7.73 Million - $8.88 Million
46,065 Added 1842.6%
48,565 $9.36 Million
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $1.49 Million - $1.73 Million
-10,200 Reduced 80.31%
2,500 $425,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $1.74 Million - $1.98 Million
12,700
12,700 $1.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.